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Abstract
Background: The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) performs annual
sentinel surveillance of Neisseria gonorrhoeae susceptibility to therapeutically relevant antimicrobials across the
European Union/European Economic Area (EU/EEA). We present the Euro-GASP results from 2016 (25 countries),
linked to patient epidemiological data, and compared with data from previous years.
Methods: Agar dilution and minimum inhibitory concentration (MIC) gradient strip methodologies were used to
determine the antimicrobial susceptibility (using EUCAST breakpoints) of 2660 N. gonorrhoeae isolates from 25
countries across the EU/EEA. Significance of differences compared with Euro-GASP results in previous years was
analysed using Z-tests.
Results: No isolates with resistance to ceftriaxone (MIC > 0.125mg/L) were detected in 2016 (one in 2015). However,
the proportion of isolates with decreased susceptibility to ceftriaxone (MICs from 0.03mg/L to 0.125mg/L) increased
significantly (p = 0.01) from 2015 to 2016. There were 14 (0.5%) isolates with ceftriaxone MICs 0.125mg/L (on the
resistance breakpoint), of which one isolate was resistant to azithromycin and four showed intermediate susceptibility
to azithromycin. Cefixime resistance was detected in 2.1% of isolates in 2016 compared with 1.7% in 2015 (p = 0.26)
and azithromycin resistance in 7.5% in 2016 compared with 7.1% in 2015 (p = 0.74). Seven (0.3%) isolates from five
countries displayed high-level azithromycin resistance (MIC≥256mg/L) in 2016 compared with five (0.2%) isolates in
2015. Resistance rate to ciprofloxacin was 46.5% compared with 49.4% in 2015 (p = 0.06). No isolates were resistant to
spectinomycin and the MICs of gentamicin remained stable compared with previous years.
Conclusions: Overall AMR rates in gonococci in EU/EEA remained stable from 2015 to 2016. However, the ceftriaxone
MIC distribution shifted away from the most susceptible (≤0.016mg/L) and the proportion of isolates with decreased
susceptibility to ceftriaxone increased significantly. This development is of concern as current European gonorrhoea
management guideline recommends ceftriaxone 500mg plus azithromycin 2 g as first-line therapy. With azithromycin
resistance at 7.5%, the increasing ceftriaxone MICs might soon threaten the effectiveness of this therapeutic regimen
and requires close monitoring.
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Background
The treatment and control of gonorrhoea during the last
decade has been under serious threat due to the emer-
gence and spread of antimicrobial resistance (AMR) in
Neisseria gonorrhoeae. Ceftriaxone is the last remaining
option for effective empiric first-line antimicrobial
monotherapy. The current European gonorrhoea man-
agement guideline recommends combination treatment
with ceftriaxone plus azithromycin in an attempt to
mitigate the development and/or spread of resistance to
these antimicrobials [1]. Susceptibility to these antimi-
crobials has decreased internationally in the past [2, 3],
and in 2018, the first gonococcal strain with ceftriaxone
resistance combined with high-level resistance to azi-
thromycin was reported from England [4], which was
followed by two similar cases in Australia [5]. Therefore,
surveillance of gonococcal susceptibility, including mon-
itoring current and emerging trends in AMR, is essential
in order to ensure effective patient management [6, 7].
Since 2009, the European Gonococcal Antimicrobial
Surveillance Programme (Euro-GASP), coordinated by
the European Centre for Disease Prevention and Control
(ECDC) and supported by a European network of micro-
biologists and epidemiologists, has strengthened the sur-
veillance of gonococcal antimicrobial susceptibility in
the European Union (EU)/European economic area
(EEA), in order to provide quality-assured data to inform
gonorrhoea treatment guidelines. Euro-GASP has identi-
fied decreasing susceptibility to extended-spectrum
cephalosporins in the past and treatment failures have
been documented [6–9], prompting the creation and
subsequent implementation of a European response plan
to control and manage the threat of multidrug-resistant
N. gonorrhoeae in Europe [7].
This study presents the results from the 2016 Euro-
pean gonococcal antimicrobial susceptibility sentinel
surveillance, in conjunction with patients’ epidemio-
logical data, and compares the results to data from pre-
vious years.
Methods
European gonococcal antimicrobial surveillance
Programme (euro-GASP)
Participating laboratories from 25 EU/EEA countries
(Table 1) collected N. gonorrhoeae isolates from con-
secutive patients (one isolate per patient) from Septem-
ber to November 2016 unless sufficient numbers could
not be achieved during this time frame, in which case
isolates were collected throughout the year. The United
Kingdom (UK) collected isolates from July to September
2016 (to coincide with the collection in the national
Gonococcal Resistance to Antimicrobials Surveillance
Programme (GRASP) [10]) and isolates were selected
from this collection to give full UK geographical
representation. The isolate collection period was the
same as 2015. Full details of the Euro-GASP N. gonor-
rhoeae isolate collection and selection criteria can be
found in the Euro-GASP protocol [11]. Antimicrobial
susceptibility testing was performed using MIC gradient
strip tests or agar dilution methods (determination of
minimum inhibitory concentration (MIC) or breakpoint
technique) for ceftriaxone, cefixime, azithromycin, cipro-
floxacin, spectinomycin and gentamicin as previously de-
scribed [11]. Since 2014, spectinomycin and gentamicin
are only tested every 3 years as they are not in routine
use for treatment, susceptibility has appeared to be sta-
bly high, and spectinomycin is difficult to acquire. Iso-
lates from eight (32%) countries (Table 1) were tested
centrally at Public Health England or Örebro University
Hospital, Sweden with the remaining 17 (68%) countries
performing antimicrobial susceptibility testing in their
own laboratories (these laboratories successfully fulfilled
established quality criteria prior to commencing their
own testing). All Euro-GASP laboratories participated in
an annual external quality assessment (EQA)
programme [12] to ensure comparability of antimicro-
bial susceptibility data. The antimicrobial susceptibility
data were interpreted into susceptibility, intermediate
susceptibility and resistance using EUCAST resistance
breakpoints: cefixime/ceftriaxone resistance MICs >
0.125 mg/L, azithromycin resistance MIC > 0.5 mg/L,
ciprofloxacin resistance MIC > 0.06 mg/L, and spectino-
mycin resistance MIC > 64 mg/L [13]. In addition to
antimicrobial susceptibility data, patient epidemiological
data were collected and categorised; age (< or ≥ 25 years);
gender and sexual orientation (men who have sex with
men (MSM), male heterosexual or female); anatomical
site of collection (urogenital, rectal, pharyngeal, other);
previous gonorrhoea (yes/no) and concurrent Chla-
mydia trachomatis infection (yes/no). The overall cover-
age of Euro-GASP was estimated by comparing the
number of isolates tested in Euro-GASP to the number
of cases reported as part of the enhanced epidemio-
logical surveillance of STI in 2016 [14].
Statistical analysis
Statistical analysis was performed using Stata v13.1 (Sta-
taCorp LP, Texas, USA). The Z-test was used to deter-
mine differences between AMR and epidemiological
data collected in 2016 versus 2015 and a Mann-Whitney
test was used to test whether the differences in age dis-
tribution were statistically significant. Where datasets
contained sufficient numbers, associations between pa-
tient epidemiological data and AMR were assessed using
odds ratios (OR) and 95% confidence intervals (CI); the
Pearson’s χ2 test was used to measure if these odds ratios
differed significantly from 1. For small cell numbers,
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Fisher’s exact test was performed. Statistical significance
for all tests was assumed when p < 0.05.
Results
During 2016, a total of 2660 isolates were tested in
Euro-GASP, which represents an increase of 526 isolates
(24.6%) compared with 2015. The number of isolates
tested from each country varied from two (Estonia) to 365
(Spain) (Table 1). The overall coverage of Euro-GASP was
4% and ranged from 1% to over 100% (indicating incom-
plete epidemiological surveillance in one country).
The epidemiological characteristics of all patients (2015
and 2016) is summarised in Table 2. Most isolates (85.1%)
were from male patients; an increase compared with 2015
(81.8%, p < 0.01). Patient ages ranged from < 1 year to 93
years with a median age of 30 years and 27.5% of patients
aged < 25 years. Males (median age 30 years) were statisti-
cally older (Mann-Whitney p < 0.0001) than females
(median age 24 years) with the highest and lowest
percentage of < 25-year-olds in the female (51.5%) and
MSM patient groups (20.1%), respectively. The anatomical
site of collection was mainly urogenital (75.5%), followed
by rectal (14.2%) and pharyngeal (6.4%). For cases where
information was available (31.9%, 849/2660), 17.2% had a
previous gonorrhoea infection (stable from 2015; 17.5%)
and 23.9% had a concurrent C. trachomatis infection,
which is an increase from 2015 (19.0%, p = 0.01, Z-test).
Among cases with known sexual orientation and gender
(64.8%, 1723/2660), 59.6% of the N. gonorrhoeae infections
were reported as heterosexually acquired (38.5% females
and 61.5% males) and 40.4% were from MSM.
No isolates displayed ceftriaxone resistance
(MIC> 0.125mg/L) in 2016 compared with one (0.05%)
in 2015 (isolated in Greece), five (0.23%) in 2014 and
seven (0.35%) in 2013. Fourteen isolates (0.5%) had a cef-
triaxone MIC of 0.125mg/L (on the resistance break-
point), of which one (7.1%) was resistant to azithromycin
(isolate collected in Norway) and four (28.6%; Spain, n = 2;
Table 1 Resistance to cefixime, azithromycin and ciprofloxacin by country, Euro-GASP (25 countries), 2016
Euro-GASP European Gonococcal Antimicrobial Surveillance Programme, No. Number, MGS MIC gradient strip test (mostly Etest strips used), AD agar dilution
method to determine the MIC of an antimicrobial, BKP Breakpoint agar dilution method, CI confidence interval of the mean %, NA not applicable (countries not
included in Euro-GASP in 2015)
aColumns shaded in green indicate a reduction in the percentage of resistant isolates from 2015 to 2016 or a continuation of zero resistance
bOne isolate tested
Note: Belgium, Germany, the Netherlands and Sweden included isolates collected from September to November, Denmark and Norway from August to November, Ireland
and Italy from August to December, Poland from July to December, the United Kingdom from July to December, and the remaining countries collected throughout the year
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Greece, n = 1; and Slovakia, n = 1) had an intermediate
susceptibility to azithromycin (MIC = 0.5mg/L). The pro-
portion of gonococcal isolates which were more suscep-
tible to ceftriaxone (MIC≤0.016mg/L) decreased in 2016
(81.7%) when compared with 2015 (84.2% p = 0.03,
Z-test). In addition, the proportion of isolates with de-
creased susceptibility to ceftriaxone (MICs from 0.032
mg/L to 0.125mg/L) increased to 17.7% in 2016 from
15.0% in 2015 (p = 0.01, Z-test) (Fig. 1).
Azithromycin resistance remained stable: 7.5%
(199/2659) in 2016 compared with 7.1% (152/2134) in
2015 (p = 0.74, Z-test). The highest azithromycin resist-
ance levels were detected in Portugal (34.5%), Norway
(16.2%) and Iceland (14.3%), which differs from 2015
when Greece (22.0%) and Ireland (18.2%) documented the
highest levels [11, 15]. Seven (0.3%) isolates displayed
high-level resistance to azithromycin (MIC≥256mg/L),
which was the highest number of high-level resistant iso-
lates recorded in Euro-GASP surveillance (2011 n = 2,
2012 n = 3, 2013 n = 1, 2014 n = 1, 2015 n = 5) (Fig. 2).
These seven isolates were obtained in Iceland (n = 2), Italy
(n = 2), Czech Republic, Ireland, and the UK (one isolate
each) and were susceptible to all the other antimicrobials
tested except for the Czech isolate that displayed cipro-
floxacin resistance. The MIC distribution for azithromycin
in 2016 was similar to previous years (Fig. 2); the majority
of resistant isolates had an MIC just above the resistance
breakpoint (0.5mg/L) and the modal MIC remained at
the same level (0.25mg/L) as in 2015. Fourteen (0.5%)
azithromycin resistant isolates were also resistant to cefix-
ime and these isolates were from Hungary (n = 8), Belgium
(n = 3), Italy (n = 1), Norway (n = 1), and Poland (n = 1).
Eighty (3.0%) azithromycin resistant isolates were also
resistant to ciprofloxacin. In 2016, as in 2015 [11],
azithromycin resistance was highest among heterosex-
ual males (7.6%) followed by MSM (5.6%) and lowest
in females (5.3%).
Cefixime resistance remained stable at 2.1% (56/2660)
in 2016 compared with 1.7%, (36/2132) (p = 0.26, Z-test)
in 2015 and remained lower than observed in
2010–2013 (4.7–8.7%) (Table 1, Fig. 3). The increased
use of MIC gradient strip tests, which can sometimes
read one MIC doubling dilution lower than agar dilution
for cefixime [16], may also have had a limited effect on
the decrease in cefixime resistance post-2013. The high-
est cefixime resistance levels were detected in Croatia
(11.1%), Luxembourg (10.0%) and Hungary (8.5%), which
differs from 2015 when Greece (11.0%) and Belgium
(11.1%) had the highest levels [11, 15]. No isolates with a
cefixime MIC of ≥0.5 mg/L were detected in 2016, which
is a decrease from seven (0.3%) isolates in 2015, three
(0.9%) isolates in 2014, 19 (0.2%) isolates in 2013, three
(1.0%) isolates in 2012, and 17 (0.1%) isolates in 2011,
[15]. The proportion of most susceptible isolates
(MIC≤0.016 mg/L) remained stable at 74.3% in 2016
compared with 75.0% in 2015 (p = 0.7, Z-test). Cefixime
resistance according to sexual orientation and gender
was stable in 2016 compared with 2015; highest in het-
erosexual males (2.2%), followed by females (2% p < 0.01,
OR = 0.91, CI = 0.38–2.2, Pearson’s χ2 test), and lowest
in MSM (0%).
Table 2 Patient characteristics 2015–2016
2015 2016
N (%) N (%)
Total number of isolates 2134 2660
Gender
Male 1736 (81.8)ǂǂ 2256 (85.1)^ ǂǂ
Female 385 (18.2)ǂǂ 395 (14.9) ǂǂ
Unknown 13 9
Age (years)
< 25 617 (29.5) 720 (27.5)
≥25 1476 (70.5) 1902 (72.5)
Unknown 41 38
Sexual orientation & gender
Females 385 (26.4)ǂǂ 395 (22.9) ǂǂ
Heterosexual males 419 (28.7)ǂǂ 632 (36.7) ǂǂ
Men who have sex with men 657 (45.0) 696 (40.4)^ ǂǂ
Unknown 673 937
Site of infection
Genital 1517 (72.9)ǂǂ 1943 (75.5)
Pharyngeal 180 (8.7) 165 (6.4) ǂǂ
Anorectal 280 (13.5)ǂǂ 366 (14.2)
Other 103 (5.0)ǂǂ 100 (3.9)
Unknown 54 86
Previous gonorrhoea
Yes 157 (17.5) 171 (17.2)
No 739 (82.5) 824 (82.8)
Unknown 1238 1665
Concurrent STI
Concurrent chlamydia infection 153†† (19.0) 203 (23.9)˜ ǂǂ
Concurrent other STI (not HIV) 48†† (6.0) 53 (6.2) ††
No concurrent STI 605 (75.1) 593 (69.9) ǂǂ
Unknown 1328 1811
HIV status
Positive 132 (15.3)ǂǂ 156 (15.9)
Negative 733 (84.7)ǂǂ 823 (84.1)
Unknown 1269 1681
Percentages calculated from known values
††Includes four individuals with two concurrent STIs
ǂǂSignificant difference compared to previous year (p < 0.05)
^Includes one individual of unknown gender, but with mode of transmission
reported as MSM
˜ Includes nine individuals with chlamydia and an additionally diagnosed STI
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Ciprofloxacin resistance remained stable at 46.5%
(1236/2660) compared with 49.4% (1054/2133) in 2015 (p
= 0.06, Z-test). Resistance was significantly associated with
heterosexual males (51.6%, p < 0.01, OR = 1.68, CI = 1.35–
2.09, Pearson’s χ2 test) and lowest in MSM (38.8%) with a
decrease in resistant isolates from both heterosexual males
(59.7% in 2015, p = 0.01, Z-test) and MSM (44.1% in 2015
p = 0.05, Z-test) from 2015 [11, 15] to 2016 with a recipro-
cal increase in females from 41.8 to 43.3% (p = 0.69,
Z-test). There was an association between ciprofloxacin
resistance and previous gonorrhoea infection (OR = 1.46,
CI = 1.05–2.04, p = 0.02), which remained in the multivari-
able analysis (OR = 1.44, CI = 1.02–2.05, p = 0.04).
Resistance to azithromycin, cefixime and ciprofloxacin
continued to be less common in anorectal isolates (4.6%;
0%; 36.1% respectively) than in urogenital (7.7%; 2.4%;
48.4%) or pharyngeal (7.9%; 0.6%; 38.8%) isolates.
As in previous testing years, there was no spectino-
mycin resistance detected amongst the 2018 isolates
tested across 20 countries. Currently, there are no
breakpoints for gentamicin but the MICs continued to
be low across all 15 countries that tested 1507 isolates
for gentamicin susceptibility in 2016. The MIC ranged
from 0.5 mg/L to 16 mg/L with a modal MIC of 4 mg/L
which is lower than when last tested in 2013 (modal
MIC = 8 mg/L) [17]. This is likely due to a change in
methodology with an increased use of Etests in 2016
(83.4% tested by Etest in 2016, 43.6% in 2013) which
frequently read one dilution lower than agar dilution
for gentamicin [18].
Fig. 1 Trends in resistant Neisseria gonorrhoeae isolates by antimicrobial and year, Euro-GASP, 2009–2016. Percentage of resistant isolates on logarithmic
scale on y-axis. Number of ceftriaxone resistant isolates; 2009 and 2010 n= 0, 2011 n= 10, 2012 n= 3, 2013 n= 7, 2014 n= 5, 2015 n= 1, and 2016 n= 0
Fig. 2 Azithromycin MIC distribution in Euro-GASP, 2011–2016
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Discussion
In the EU/EEA, resistance to extended-spectrum cephalo-
sporins remained stable in 2016 with a decrease in the pro-
portion of highly resistant isolates to cefixime (≥0.5mg/L).
However, a reduction in the proportion of isolates highly
susceptible to ceftriaxone was observed, which has also
been reported from other countries, e.g., China [19]
(Changsha 2003–2015 [20], Shandong 2007–2014 [21])
and Argentina (2012–2013) [22] highlighting decreasing
ceftriaxone susceptibility in several settings globally.
Azithromycin resistance remained stable at 7.5% in
2016 in EU/EEA, which is comparable to that in the
United States (11.1% in 2016 (recalculated using EUCAST
breakpoints) [23]), Guangzhou, China (9.1% 2009–2013
[24]) and New Zealand (10.8% 2014–2015 [25]), but
higher than that observed in Australia (2.6% in 2015 [26])
and Canada (4.7% in 2015 [27]). Notably, different azithro-
mycin resistance breakpoint were used in Canada (MIC≥2
mg/L [27]) and the United States (MIC≥2mg/L [23]),
which illustrates the difficulties of comparing gonococcal
AMR data from different regions or countries and the im-
portance of reporting MIC distributions. Many isolates
show MICs close to the EUCASTazithromycin breakpoint
which causes resistance rates to fluctuate widely over years
which can over emphasise minor shifts in MICs. The in-
duction and/or selection of azithromycin resistance in N.
gonorrhoeae by the use of dual therapy for gonorrhea is
likely limited [28]. Accordingly, the resistance to azithro-
mycin is likely mostly a bystander effect as a consequence
of the widespread use of azithromycin monotherapy to
treat respiratory tract infections, C. trachomatis infections,
and/or male non-gonococcal urethritis, which may explain
the higher level of azithromycin resistance observed in
males in EU/EEA. Increases in N. gonorrhoeae isolates
with decreased susceptibility to azithromycin from MSM
have been observed in Seattle, USA between 2012 and
2016 [29] and more widely across the USA 2013–2014
[30]. Fourteen (7.0%) of the 199 azithromycin resistant
isolates in 2016 in EU/EEA were also resistant to cefixime,
which is a worrying development that highlights the im-
portance of conserving the efficacy of ceftriaxone as treat-
ment options are becoming increasingly restricted.
Among MSM in EU/EEA, cefixime resistance has
remained low and fairly steady since 2013 and MSM re-
main the risk group with the lowest level of cefixime re-
sistance (0% in 2016). There was a decrease in
ciprofloxacin resistance from 2015 (44.1%) to 2016
(38.8%) further supporting the previous finding that MSM
currently have a lower risk of harbouring resistant isolates
[31]. This is in contrast to the findings in the USA where
the percentage of isolates resistant to ciprofloxacin were
greater in MSM than in heterosexuals [30].
Even though the number of countries participating
(currently 25 (81%) of the 31 EU/EEA countries) and
number of isolates in Euro-GASP increased in 2016, the
percentage of isolates tested in Euro-GASP compared
with the number of gonorrhoea cases reported has de-
creased from 6% in 2009 to 4% in 2016, which is mainly
a result of the increase in the overall number of gonor-
rhoea cases diagnosed in the EU/EEA [14]. A detailed
review of the number and characteristics of the gono-
coccal isolates submitted to Euro-GASP and their corre-
sponding gonorrhoea patient data is required in order to
ensure that Euro-GASP data remain representative of
Fig. 3 Ceftriaxone MIC distribution in Euro-GASP, 2009–2016
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the European N. gonorrhoeae population. One of the
aims of Euro-GASP is to develop capacity for culture
and antimicrobial susceptibility testing across countries
allowing for increased numbers of isolates to be included
in the study. Additional limitations of Euro-GASP in-
clude, as in most national and particularly international
GASPs, lower number of isolates from females (15% of
isolates in 2016), suboptimal level of reporting of some
key epidemiological data such as sexual orientation (sex-
ual orientation and gender were reported for 65% of
Euro-GASP cases in 2016), as well as low number and
likely suboptimal representativeness of isolates from
some countries (e.g. Croatia, Estonia and Latvia) and the
need to include six EU/EEA countries. Consequently, it
remains crucial to improve the representativeness of
Euro-GASP data, which is also part of the ongoing
Euro-GASP work programme.
Conclusions
Even though Euro-GASP detected no resistance to ceftri-
axone, stably low resistance to cefixime (2.1%) and stable
azithromycin resistance (7.5%) in 2016, the decreasing cef-
triaxone susceptibility and the relatively high azithromycin
resistance, including isolates with very high azithromycin
MICs (≥256mg/L), is of major concern. The European re-
sponse plan to control the threat of multidrug-resistant N.
gonorrhoeae in Europe [7] should continue to be imple-
mented to increase the quality-assured gonococcal AMR
surveillance and to support timely identification and
reporting of treatment failures and ensure that gonorrhoea
remains a treatable infection. Euro-GASP continues to ful-
fil the objectives of the response plan which include
strengthening the surveillance of gonococcal antimicrobial
susceptibility by increasing the number of participating
countries and isolates and improving representativeness of
the programme, advocating the use of recommended dual
therapy (ceftriaxone 500mg and azithromycin 2 g) to treat
gonorrhoea [1], which appears highly effective, and ensur-
ing that all Euro-GASP laboratories continue to partici-
pate in the EQA programme.
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